Back to top
more

Enhabit, Inc. (EHAB)

(Delayed Data from NYSE)

$7.80 USD

7.80
1,546,860

+1.03 (15.21%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $7.80 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (97 out of 244)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Enhabit (EHAB) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Enhabit (EHAB) delivered earnings and revenue surprises of +30.00% and +1.14%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Performant Healthcare (PHLT) Surges 115.2%: Is This an Indication of Further Gains?

by Zacks Equity Research

Performant Healthcare (PHLT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

All You Need to Know About Enhabit (EHAB) Rating Upgrade to Buy

by Zacks Equity Research

Enhabit (EHAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Strength Seen in Progyny (PGNY): Can Its 13.2% Jump Turn into More Strength?

by Zacks Equity Research

Progyny (PGNY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Enhabit (EHAB) Q1 Earnings Top Estimates

by Zacks Equity Research

Enhabit (EHAB) delivered earnings and revenue surprises of 42.86% and 2.56%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CVS Health (CVS) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

CVS Health (CVS) delivered earnings and revenue surprises of 31.58% and 1.76%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is Enhabit, Inc. (EHAB) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Enhabit (EHAB) and Doximity (DOCS) have performed compared to their sector so far this year.

Zacks Equity Research

Danaher Gains From Strength in the Diagnostics Unit Amid Headwinds

by Zacks Equity Research

DHR is poised to gain from strength in the clinical diagnostics business, the Abcam buyout and shareholder-friendly policies. Softness in Life Sciences and Biotechnology units remains a concern.

Zacks Equity Research

Why Fast-paced Mover Enhabit (EHAB) Is a Great Choice for Value Investors

by Zacks Equity Research

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Enhabit (EHAB) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

Is Bayer (BAYRY) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Bayer Aktiengesellschaft (BAYRY) and Enhabit (EHAB) have performed compared to their sector so far this year.

Zacks Equity Research

Surging Earnings Estimates Signal Upside for Enhabit (EHAB) Stock

by Zacks Equity Research

Enhabit (EHAB) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

Here's Why You Should Avoid Betting on Danaher Stock Right Now

by Zacks Equity Research

Persistent softness in the Life Sciences segment weighs on DHR's performance. An increase in operating expenses is an added concern.

Zacks Equity Research

Enhabit (EHAB) Q4 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Enhabit (EHAB) delivered earnings and revenue surprises of -20% and 0.37%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Viatris (VTRS) Q4 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Viatris (VTRS) delivered earnings and revenue surprises of -5.26% and 2.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Enhabit (EHAB) Is Attractively Priced Despite Fast-paced Momentum

by Zacks Equity Research

Enhabit (EHAB) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Zacks Equity Research

Enhabit (EHAB) Shows Fast-paced Momentum But Is Still a Bargain Stock

by Zacks Equity Research

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Enhabit (EHAB) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

UnitedHealth's $3.3B Merger Stalls as VitalCaring Sale Falls Through

by Zacks Equity Research

UNH and AMED are now expected to identify new buyers for the divestment assets by March 2025.

Zacks Equity Research

Are Options Traders Betting on a Big Move in Enhabit (EHAB) Stock?

by Zacks Equity Research

Investors need to pay close attention to Enhabit (EHAB) stock based on the movements in the options market lately.

Zacks Equity Research

Enhabit (EHAB) Misses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Enhabit (EHAB) delivered earnings and revenue surprises of -25% and 3.09%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Do Options Traders Know Something About Enhabit (EHAB) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Enhabit (EHAB) stock based on the movements in the options market lately.

Zacks Equity Research

Enhabit (EHAB) Q2 Earnings Surpass Estimates

by Zacks Equity Research

Enhabit (EHAB) delivered earnings and revenue surprises of 16.67% and 2.03%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here Is Why Bargain Hunters Would Love Fast-paced Mover Enhabit (EHAB)

by Zacks Equity Research

Enhabit (EHAB) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

Enhabit (EHAB) Upgraded to Strong Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Enhabit (EHAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

Earnings Preview: Viatris (VTRS) Q2 Earnings Expected to Decline

by Zacks Equity Research

Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Enhabit (EHAB) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Enhabit (EHAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.